



Comparison of Common Molecular Typing Methods for Differentiation of *Clostridium difficile* Strains in the Study of Hospital Acquired Diarrhea

Masoumeh Azimirad^{1,2}, Masoud Alebouyeh^{1,*}, Marjan Rashidan³, Mohammad Mehdi Aslani⁴ and Mohammad Reza Zali⁵

¹Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

³School of Medicine, Shahrood University of Medical Sciences, Shahrood, Iran

⁴Microbiology Department, Pasteur Institute of Iran, Tehran, Iran

⁵Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: PhD, Medical Bacteriology, Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Tel: +98-2122432518, Fax: +98-2122432517, E-mail: masoud.alebouyeh@gmail.com

Received 2017 August 29; Revised 2018 May 20; Accepted 2018 June 10.

Abstract

Background: Cross-contamination between patients and the medical imaging device is a worldwide concern. In the current study, the ability of different molecular typing methods for differentiation of *Clostridium difficile* isolates from patients and medical devices was compared to show their discriminatory power for molecular epidemiological purposes.

Methods: A total of 23 *C. difficile* strains from fresh stool samples of patients subjected to colonoscopy, medical device, and environmental samples of a gastroenterology unit were used for molecular typing. Similarity of the strains was determined by the polymerase chain reaction (PCR) ribotyping, capillary gel electrophoresis based-ribotyping, and RAPD-PCR and ERIC-PCR methods. Phylogenetic analysis of the molecular patterns was done by the GelCompar II software and discriminatory power of the methods was measured using Simpson's index diversity.

Results: RAPD-PCR and PCR-ribotyping methods showed the highest discrimination power for differentiation of the studied strains, while genotyping showed the lowest power. Similarity of *C. difficile* strains between the patients and medical equipment was detected for the strains presenting PCR-ribotypes B and CE-ribotype 150.

Conclusions: Involvement of medical device for transmission of toxigenic strains of *C. difficile* was determined in this study. Although diversity of *C. difficile* strains was established in the studied hospital, a discrepancy was detected among these techniques for typing purposes. The results suggested the usage of a combination of two or more typing methods for detection of sources of cross-contamination in each hospital.

Keywords: Genotyping, Ribotyping, Random Amplified Polymorphic DNA Technique, *Clostridium difficile*, Cross-Contamination.

1. Background

Clostridium difficile are gram-positive spore-forming anaerobic bacteria that are considered as the causative agent for 15% to 25% of antibiotic associated diarrhea (AAD) and also pseudomembranous colitis (PMC) (1, 2).

The majority of *C. difficile* strains produce two cellular cytotoxins, TcdA, and TcdB; however, a small percentage of pathogenic strains produce truncated nonfunctional toxins. These genes are located within a 19.6-kb genomic pathogenicity locus (PaLoc), where their expression are

regulated by *tcdC* and *tcdD*. A third toxin, the *C. difficile* binary toxin (CDT), which functions independently of PaLoc-associated regulatory elements (3, 4), has been identified in approximately 5% of the clinical isolates. Severity of diseases caused by *C. difficile* mainly depends on types of these virulence genes and their combination in each strain.

Although most cases of *C. difficile* infection (CDI) occur by endogenous strains after antibiotic therapy, numerous hospital outbreaks were caused through patient-to-patient contact, and contact with the hospital environment and health care workers. Detection of the main sources of in-

fection at hospital wards that are at higher risk of CDI is important for both disease control and its prevention.

Several techniques, such as pulsed field gel electrophoresis (PFGE), restriction fragment length polymorphism (RFLP), arbitrarily primed PCR (AP-PCR), PCR ribotyping, toxinotyping, and enterobacterial repetitive intergenic consensus-PCR (ERIC-PCR) have been developed to investigate epidemiology of CDI at the local level (2, 5). However, some techniques may lack sufficient discriminatory power and misclassify the strains. PCR-ribotyping, which is based on size variation of intergenic spacer region (ISR) of ribosomal operon, is the standard typing method in Europe as well as Australia (5-8). Copy number of rRNA (rrn) operons in *C. difficile* usually range between 1 and 11 (4). Variation within the PaLoc region (containing toxins A and B) and other virulence genes among *C. difficile* strains has been observed frequently among *C. difficile* strains and this variation is used for distinguishing different strains from each other (9, 10). This technique is used in two conventional and automated (capillary electrophoresis) manners. Furthermore, diversity in the number of intergenic consensus sequences as palindromes of 127 bp among different strains, which is known as enterobacterial repetitive intergenic consensus (ERIC) sequences, proposed ERIC-PCR as a simple useful tool for molecular epidemiology of CDI (11).

In an attempt to study contamination of medical equipment with *C. difficile* strains in a gastroenterology unit, the current research compared sensitivity of four methods, PCR-ribotyping, capillary electrophoresis-ribotyping, random amplified polymorphic DNA (RAPD)-PCR assay and ERIC-PCR to determine possible sources of cross-contamination between patients and the environment. Furthermore, consistency of these molecular typing methods was evaluated to determine more simple and suitable typing methods for differentiation of *C. difficile* strains.

2. Methods

2.1. Bacterial Strains

A total of 23 *C. difficile* strains from fresh stool samples of patients subjected to colonoscopy (19/105, 18.1%), medical device (3/36, 8.3%), and environmental samples (1/17, 5.8%) of a gastroenterology unit were used for molecular typing. The isolates were obtained and identified as described previously (12). All the samples were collected from a teaching hospital in Tehran, Iran, during December 2010 to August 2011. To show possible correlation, isolates of the medical device and environmental samples were obtained at the same time points. The *C. difficile* strains were

grown anaerobically (Anoxomat, Netherlands) on *C. difficile* medium (Mast, United Kingdom) supplemented with 7% horse blood and selective components at 37°C. Identity of all isolates was characterized by the polymerase chain reaction, using specific primers (13). This study was approved by the Ethical Committee of Research Institute for Gastroenterology and Liver Diseases (Number RIGLD 613) in Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2.2. DNA Preparation and Polymerase Chain Reaction Assay

Genotyping of *C. difficile* strains for enterotoxigenic genes *tcdA* and *tcdB*, and cytolethal distending toxin (binary toxins, *cdtA* and *cdtB*) was done using specific primer pairs, as described by Spigaglia and Mastrantonio (14). Accordingly, crude DNA was extracted from the grown colonies by the InstaGene matrix extraction kit (Bio-Rad, USA) (8). The PCR-amplified products were detected by 1.2% ethidium bromide stained agarose gel electrophoresis.

2.3. PCR-Ribotyping

PCR-ribotyping was conducted in 25- μ L reaction volumes composed of 1.5 mM MgCl₂, 10 mM Tris-HCl, 50 mM KCl, 2.5 U Taq DNA polymerase, 200 mM of each dNTP, 50 pmol of each primer, and 1 μ L of each DNA template. Primers P3 (5'-GCGCCCTTGTAGCTTGACC-3') and P5 (5'-CTGGGGTGAAGTCGTAACAAG-3') were used for the PCR amplification (Ltd., Shiga, Takara Shuzo Co.). The following time-temperature profile was used consistently for each sample: One cycle of five minutes at 94°C for initial denaturation; 35 cycles of one minute at 94°C, one minute at 55°C, and one minute at 72°C; and a final extension cycle of five minutes at 72°C. The amplification products were concentrated to a final volume of 25 μ L by heating at 75°C for 20 minutes before electrophoresis, and visualized as described above. The images were analyzed by the Gel ComparII image analysis software (version 3.5, Applied Math) (15). Capillary electrophoresis (CE) ribotyping was performed according to the new consensus ribotyping protocol (12) at the Department of Medical Microbiology, Motol University Hospital, Prague, Czech Republic. The obtained CE-ribotyping profiles were compared with the profiles used in CE-ribotyping validation study (12). The peaks in the chromatogram files (fsa file format) were also uploaded to the WEBRIBO database (16).

2.4. RAPD-PCR Assay

The RAPD-PCR was performed with a single arbitrary primer, 1254 (5'-CCGCAGCCAA-3'). A volume of 25 μ L containing 1X PCR buffer, 1.25 μ M of each primer, 7 μ L of genomic DNA, 200 μ M of dNTPs mix, 2.5 mM of MgCl₂, and

0.05 U/ μ L Taq DNA polymerase was used for each reaction. The RAPD-PCR amplification was performed in an automated thermal cycler (AG 22331; Eppendorf, Hamburg, Germany) under the following conditions: Four cycles of five minutes at 94°C, one minute at 36°C, two minutes at 72°C followed by 35 cycles of one minute at 94°C, one minute at 36°C, and two minutes at 72°C. Similarity of all RAPD banding profiles was analyzed by the GelCompar II Software. Polymorphisms of ≤ 2 and > 2 RAPD bands were considered as definitive criteria for detection of related and different strains, respectively.

2.5. ERIC-PCR Fingerprinting

The primers ERIC1R (5'-ATGTAAGCTCCTGGGGATTAC-3') and ERIC2 (5'-AAGTAA GTGACTGGGGTGAGCG-3') were used for the PCR amplification (17). All PCR amplifications were performed in 25- μ L volumes containing 3 μ L of template DNA, 1 mM concentrations of deoxynucleoside triphosphates, 2.5 μ L of 10X PCR buffer, 1 mM MgCl₂, 1 μ M concentrations of each forward and reverse primer, 2 U of Taq DNA polymerase at the following conditions: Initial denaturation step at 95°C for seven minutes, followed by 30 cycles of denaturation at 95°C for 30 seconds, 52°C annealing for one minute, and extension at 65°C for eight minutes. After the last cycle, the mixture was incubated at 68°C for 16 minutes (17). The amplification product was analyzed by electrophoresis on a 1.8% agarose gel by a standard protocol after staining with ethidium bromide and visualization on a gel documentation system. Similarity of all ERIC-PCR banding profiles was analyzed by the GelCompar II Software. Relatedness of the strains was characterized in a similar manner that was described for the RAPD-PCR method.

2.6. Statistical Analysis

For analysis of discriminatory power, the current researchers used an index of discrimination for in silico simulation of molecular biology experiments (Discriminatory Power Calculator). Confidence intervals for D were determined by the method described previously by Grundmann et al. (18). Significant differences of the studied assays were estimated using Chi-squared and Fisher's exact tests.

3. Results

To study possible homology of the *C. difficile* strains responsible for nosocomial diarrhea, the researchers isolated 19 *C. difficile* strains from symptomatic patients, (nine males and ten females) and four isolates from medical devices and the environment of a gastroenterology unit (Colonoscope, forceps of the endosonographic imaging

system, forceps of the ERCP device and patients' bed during the study period). Strain RIGLD-141 was used as the control strain for all the conventional microbiological and molecular experiments.

3.1. Toxin Genotyping

Genotyping of the strains for *tcdA* and *tcdB* showed one strain as *tcdA*⁻/*tcdB*⁻ (4.34%) and 22 strains as *tcdA*⁺/*tcdB*⁺ (95.65%). The studied strains also showed *cdtA*⁻/*cdtB*⁻ (78.26%; 18/23) and *cdtA*⁺/*cdtB*⁺ (21.73%; 5/23) genotypes for binary toxin encoding genes (Table 1).

3.2. RAPD Typing

The RAPD-PCR was performed on crude DNA extracts of the *C. difficile* strains for determination of their genetic relatedness. The PCR results for primer 1283 showed its limitation for discrimination of different *C. difficile* strains in production of useful banding patterns. In case of primer 1254, five strains did not generate the RAPD patterns; however, 17 different strains were characterized based on their RAPD types (Figure 1A). Cross contamination between the imaging equipment and the patients was shown for the strains presenting RAPD patterns XIV (supplementary file appendix 1). Similarity of RAPD-PCR patterns are shown in Figure 1A. The RAPD typing showed high discriminatory power and stability for analysis of these strains (Table 2).

3.3. PCR-Ribotyping

Results of the conventional PCR ribotyping method showed that all, but one strain, were typeable by this assay. The obtained ribotype patterns exhibited seven to ten bands ranging from 300 to 1100 bp (Figure 1B). A total of 15 different ribotype patterns were found among the 23 studied strains. The predominant type was ribotype B, which belonged mostly to the strains from the patient's fecal samples. Cross contamination of *C. difficile* strains between the patients and also medical equipment was seen in strains presenting ribotypes B (Figure 1B and Table 1). All the other strains were characterized as singletons and represent unique ribotypes. Similarity between ribotyping patterns are shown in Figure 1.

3.4. CE-Ribotyping

Results of CE-ribotyping showed ten different ribotypes based on the CE-profiles that were recognized by WEBRIBO. Three CE-profiles were not identified and two DNA samples were not repeatedly amplified by the primers used for this assay.

Table 1. Molecular Characteristic of *C. difficile* Strains Isolated From the Patients and a Medical Device of a Gastroenterology Unit

ID code	Source	tcdAB	cdtA	cdtB	CE-Ribotyping	PCR-Ribotyping	RAPD	ERIC PCR
32-2	Colonoscopy device	AB	Neg	Neg	150/Al-12	D	VII	J
114-2	Patient	AB	Neg	Neg	150/Al-12	C-Like	XII	H
184-2 ^a	Patient	AB ^a	Neg ^a	Neg ^a	001 ^a	B	XIV ^a	C-like
75-2 ^a	ERCP device	AB ^a	Neg ^a	Neg ^a	001 ^a	A	XIV ^a	B
54-2 ^a	Endoscopy device	AB ^a	Pos ^a	Pos ^a	126 ^a	B ^a	No pattern	M
65-2 ^a	Patient	AB ^a	Pos ^a	Pos ^a	126 ^a	B ^a	X	D
20-2	Patient	AB	Pos	Pos	126	E	No pattern	K
141-2	Patient	AB	Pos	Pos	126	F	IX	E-like
85-2	Patient	AB	Pos	Pos	126	G	VI	N-like
105-2	Patient	AB	Neg	Neg	Unknown	C	VIII	I
90-2	Patient	AB	Neg	Neg	N/A ^b	H	IV	N
83-2	Patient	AB	Neg	Neg	N/A ^b	I	V	A
60-2	Patient	AB	Neg	Neg	Unknown	J	VIII like	N-like
45-2 ^a	Patient	Neg	Neg	Neg	039	B ^a	C	F ^a
100-2 ^a	Patient	AB	Neg	Neg	081	B ^a	II	F ^a
127-2	Patient	AB	Neg	Neg	103	K	XI	A-like
40-2	Bed	AB	Neg	Neg	Al-29	L	I	K-like
142-2	Patient	AB	Neg	Neg	003	M	No pattern	K
30-2	Patient	AB	Neg	Neg	Unknown	N	B	M-like
130-2	Patient	AB	Neg	Neg	N/A ^b	B	No pattern	E
134-2	Patient	AB	Neg	Neg	029	B	No pattern	G
110-2	Patient	AB	Neg	Neg	017	O	III	L
89-2	Patient	AB	Neg	Neg	014	B	XIII	C
No. of types			3		10	15	15	14

^aNames of the strains that presented the same molecular types by at least three different methods are indicated. Internal nomenclature was used for ERIC-PCR, conventional-PCR, and RAPD-PCR patterns obtained in this study after analysis by GelComparII. The CE-ribotypes were obtained from the WEBRIBO database.
^bN/A: not available.

Table 2. Discrimination Index of the Methods Used for Typing of *C. difficile* Strains

Method	D	95% CI
Conventional ribotyping	0.87	0.4 - 1.6
CE-ribotyping	0.89	0.8 - 1.2
RAPD	0.98	0.70 - 0.85
ERIC PCR	0.93	0.57 - 1.33

Abbreviations: CI, confidence interval; D, discriminatory power.

3.5. ERIC-PCR Fingerprints

The ERIC-PCR fingerprints consisted of patterns comprised of 7 to 12 bands, with the size of the bands varying from approximately 190 to 1500 bp. Two bands (approximately 300 and 480 bp) were conserved among all isolates (Figure 1C). While the strains showed two identical (F and

K) and six related (C, E, N, A, K, and M) ERIC types, the strains provided 14 different patterns in total (supplementary file appendix 2).

3.6. Correlation of Ribotyping, Toxin Genotyping, and RAPD-PCR

Comparison of the results of all the molecular typing methods showed some diversity. Congruency of the results among the assays was observed for six strains. Two strains that showed CE-ribotype 001 (*C. difficile* isolates from ERCP and a patient) also presented similar RAPD and virulence types. Furthermore, *C. difficile* isolates from endoscope and a patient showed the same genotype, CE-ribotype and conventional ribotype (126) (Table 1). While consistency of results of ERIC-PCR and PCR ribotyping was detected for two patients isolates (45-2 and 100-2), further analysis showed their difference in CE-ribotype and virulence genotype pat-




Figure 1. (A) RAPD-PCR typing; M: DNA Ladder mix; lanes 4 and 5: Gastroenterology device; lane 2: positive control; lanes 1, 3, and 6 - 13: Patient's samples; (B) Ribotyping pattern; M: DNA Ladder mix; lanes 7 and 8: Gastroenterology device; lanes 1 - 3 and 9: Patient's samples; (C) ERIC-PCR results; M: DNA Ladder mix; lanes 7, 8: Gastroenterology device; lanes 1 - 6 and 9 - 12: Patient's samples.

terns. Results of Simpson's index diversity showed RAPD-PCR as the method with highest discrimination ability and conventional PCR-ribotyping method as the one with lowest discrimination ability.

4. Discussion

During the past 20 years, spore forming *C. difficile* were characterized as highly-resistant microorganisms to commonly used antibiotics and disinfectants (19). Outbreaks of CDAD (*C. difficile* associated disease) have emerged due

to the prescription of broad spectrum antibiotics in hospitalized patients, which mainly rely on the alteration of the intestinal microbiota and overgrowth of the colonized spores or resistance strains in this tissue (20, 21). Infection with these bacteria could be caused by both endogenous and exogenous routes (19). Application of inappropriate disinfected medical devices, admission of patients to hospitals with poor health services, and usage of contaminated medical foods are the main risk factors for acquisition of *C. difficile* in these patients (22). Results of this study showed contamination of the gastroenterology




Figure 2. Comparison of PCR-ribotypes of *C. difficile* isolates from patients' fecal samples and gastroenterology imaging device. Homology and diversity of PCR-ribotypes of *C. difficile* strains were analyzed by GelCompar II software. Correlation of the obtained patterns with toxin genotypes and RE patterns is shown in the table. Dash line represents homology of five strains (100-2 [patient], 134-2 [patient], 45-2 [patient], 54-2 [Endoscopy device], and 130-2 [Patient]) based on the obtained ribotype patterns.

imaging devices. There are a few reports about the recovery of *C. difficile* from medical equipment and its transmission to patients in hospital settings (23-25). Molecular relatedness of *C. difficile* strains from medical equipment and patients' clinical samples was only established in one study by Dumford et al. (24). However, none of these strains were isolated from gastrointestinal imaging devices. According to the author's knowledge, this is the first report that presented the occurrence of cross contamination of *C. difficile* between a gastrointestinal imaging device and patients, who were subjected to examination

by this equipment. The noted contamination could be explained by non-standard washing and sterilization process of the equipment at the studied hospital (glutaraldehyde 2% and 10 minutes of sterilization), which occurred because of the high number of admitted patients for the examination.

Emergence of hyper virulent strains of *C. difficile*, BI/NAP1/027, in North America and Europe, has increased attention of physicians for elimination of hospital sources of infection in the recent years (26). Because of the worldwide emergence of virulent strains of *C. difficile*, epidemi-

ology of this organism and investigation of its role in CDI seems to be important (27, 28). There are a variety of different phenotyping and molecular typing methods that were proposed for epidemiology of CDI (28). Both of the methods have some limitations, however, molecular typing methods provide greater levels of typeability (29). Furthermore, RAPD-PCR and PCR ribotyping, are among commonly applied methods for molecular typing of *C. difficile* strains in clinical and non-clinical samples (30-34). It was expected for these typing methods to be able to cluster the same isolates in similar genetic profiles (28). However, discriminatory power of these methods for different strains was not clear. Tenover et al. by analyzing a greater numbers of isolates, showed that PCR-ribotyping provides higher levels of strain discrimination than PFGE. Weakness of PCR-ribotyping in discrimination of outbreak strains was described by Killgore et al. However, these authors presented a superior discrimination ability for PCR-ribotyping compared with toxinotyping methods (28). Brazier showed PCR ribotyping, among the other molecular typing methods, as a more discriminative and reproducible method (29). On the basis of the results, it appeared that all the studied techniques were able to type most of the isolates (14 types by the ribotyping method). However, the RAPD-PCR technique showed higher discriminatory power than the others (17 types). The current results are comparable with those reported by Green et al. (32). They showed that PCR ribotyping in conjunction with RAPD-PCR assay categorized different types within defined PCR ribotypes. They showed different RAPD types of *C. difficile* within the strains with the same PCR ribotype and concluded that combination of PCR ribotyping and RAPD technique could provide a greater discriminatory power than either of the methods when used alone. Van Dijk et al. by studying 56 toxigenic isolates, indicated that combination of the RAPD-PCR technique and PFGE could determine genetic diversity within toxigenic *C. difficile* isolates (35). Barbut et al. reported on the RAPD assay as a valuable tool for epidemiological studies of *C. difficile* (36). An excellent correlation was obtained between the results of RAPD and PFGE, and ribotyping in a study by Chachaty et al. for clustering of *C. difficile* isolates. Their study showed that PFGE and RAPD-PCR had similar discriminatory power (26 different types by PFGE, 25 by RAPD, and 18 types by ribotyping). In case of ERIC-PCR, the current research found that this method had the lowest discriminatory power in comparison with the other methods. In accordance with the current results, Rahmati et al. showed that ERIC-PCR could not discriminate different strains of *C. difficile* (37).

Molecular relatedness of *C. difficile* strains from hospital wards and patient samples was only established in a comprehensive study by Dumford et al. Results of this

study showed that CDI incidence correlated with the prevalence of environmental *C. difficile* in hospital wards. In their study, RAPD and RS PCR (RNA template-specific polymerase chain reaction) typing showed similar discriminatory power (38). The presence of *C. difficile* strains with similar molecular types in the studied patients was comparable with those seen in Europe, particularly the UK (39), Hungary (40), and Poland (41). They showed ribotype 001 as a responsible strain for 55% *C. difficile* infection in UK hospitals and ribotype 078 for 39% of all the isolates in Hungary. On the other hand, the association of all the environmental isolates and 35% of the neonatal isolates was established in Poland (41). Dominance of some ribotypes and their involvement in nosocomial diarrhea was reported by some studies. In a study by Rotimi et al., two ribotypes were responsible for over one-third of the cases of CDAD in Kuwaiti hospitals (42). In a European survey, among thirty-eight hospitals in fourteen different countries, sixty-six different PCR ribotypes were characterized among 322 toxigenic strains of *C. difficile*, which was higher than those obtained in the current study (10 ribotypes among 23 strains) (40, 43, 44). In the current experiment, *C. difficile* CE-ribotype 126 and conventional ribotype B were the most common ribotypes among the studied patients.

4.1. Conclusion

In conclusion, cross contamination of *C. difficile* between patients and a medical imaging device was established by different molecular typing methods in the current study. Although PCR-ribotyping, CE-ribotyping, RAPD-PCR, and ERIC PCR methods were able to show diversity of *C. difficile* strains, there was some diversity among these techniques for typing purposes. None of the studied methods was able to detect the identical strains solely. While RAPD-PCR and ERIC-PCR showed the highest discriminative power for differentiation of the *C. difficile* strains in the current study, their weakness was shown due to inconsistency in comparison to results of the other typing methods. These results proposed usage of a combination of two or more typing methods for better assessment of diversity among them.

Supplementary Material

Supplementary material(s) is available [here](#) [To read supplementary materials, please refer to the journal website and open PDF/HTML].

Acknowledgments

This study was part of a project that supported by Foodborne and Waterborne Diseases Research Center, Research

Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. The authors would like to thank Prof. Marcela Krutova and Prof. Otakar Nyc from Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic for providing CE-Ribotype data and valuable comments on our study.

References

- Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. *N Engl J Med*. 2002;**346**(5):334-9. doi: [10.1056/NEJMc011603](https://doi.org/10.1056/NEJMc011603). [PubMed: [11821511](https://pubmed.ncbi.nlm.nih.gov/11821511/)].
- Lopez-Urena D, Quesada-Gomez C, Rodriguez C, Chaves-Olarte E. Role of Clostridium difficile toxins in antibiotic-associated diarrhea and pseudomembranous colitis. *Microb Toxins*. 2016;1-18. doi: [10.1007/978-94-007-6725-6_17-1](https://doi.org/10.1007/978-94-007-6725-6_17-1).
- Barth H, Aktories K, Popoff MR, Stiles BG. Binary bacterial toxins: Biochemistry, biology, and applications of common Clostridium and Bacillus proteins. *Microbiol Mol Biol Rev*. 2004;**68**(3):373-402. table of contents. doi: [10.1128/MMBR.68.3.373-402.2004](https://doi.org/10.1128/MMBR.68.3.373-402.2004). [PubMed: [15353562](https://pubmed.ncbi.nlm.nih.gov/15353562/)]. [PubMed Central: [PMC515256](https://pubmed.ncbi.nlm.nih.gov/PMC515256/)].
- Sadeghifard N, Gurtler V, Beer M, Seviour RJ. The mosaic nature of intergenic 16S-23S rRNA spacer regions suggests rRNA operon copy number variation in Clostridium difficile strains. *Appl Environ Microbiol*. 2006;**72**(11):7311-23. doi: [10.1128/AEM.01179-06](https://doi.org/10.1128/AEM.01179-06). [PubMed: [16980415](https://pubmed.ncbi.nlm.nih.gov/16980415/)]. [PubMed Central: [PMC1636144](https://pubmed.ncbi.nlm.nih.gov/PMC1636144/)].
- Rupnik M, Brazier JS, Duerden BI, Grabnar M, Stubbs SL. Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. *Microbiology*. 2001;**147**(Pt 2):439-47. doi: [10.1099/00221287-147-2-439](https://doi.org/10.1099/00221287-147-2-439). [PubMed: [11158361](https://pubmed.ncbi.nlm.nih.gov/11158361/)].
- Janezic S, Rupnik M. Molecular typing methods for Clostridium difficile: Pulsed-field gel electrophoresis and PCR ribotyping. *Methods Mol Biol*. 2010;**646**:55-65. doi: [10.1007/978-1-60327-365-7_4](https://doi.org/10.1007/978-1-60327-365-7_4). [PubMed: [20597002](https://pubmed.ncbi.nlm.nih.gov/20597002/)].
- Kuijper EJ, van den Berg RJ, Brazier JS. Comparison of molecular typing methods applied to Clostridium difficile. *Methods Mol Biol*. 2009;**551**:159-71. doi: [10.1007/978-1-60327-999-4_13](https://doi.org/10.1007/978-1-60327-999-4_13). [PubMed: [19521874](https://pubmed.ncbi.nlm.nih.gov/19521874/)].
- O'Neill G, Ogunsoola F, Brazier J, Duerden B. Modification of a PCR ribotyping method for application as a routine typing scheme for Clostridium difficile. *Anaerobe*. 1996;**2**(4):205-9. doi: [10.1006/anae.1996.0028](https://doi.org/10.1006/anae.1996.0028).
- Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmee M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. *J Clin Microbiol*. 1998;**36**(8):2240-7. [PubMed: [9665999](https://pubmed.ncbi.nlm.nih.gov/9665999/)]. [PubMed Central: [PMC105025](https://pubmed.ncbi.nlm.nih.gov/PMC105025/)].
- Rupnik M, Kato N, Grabnar M, Kato H. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. *J Clin Microbiol*. 2003;**41**(3):1118-25. [PubMed: [12624039](https://pubmed.ncbi.nlm.nih.gov/12624039/)]. [PubMed Central: [PMC150296](https://pubmed.ncbi.nlm.nih.gov/PMC150296/)].
- Ramazan-zadeh R, Zamani S, Zamani S. Genetic diversity in clinical isolates of Escherichia coli by enterobacterial repetitive intergenic consensus (ERIC)-PCR technique in Sanandaj hospitals. *Iran J Microbiol*. 2013;**5**(2):126-31. [PubMed: [23825729](https://pubmed.ncbi.nlm.nih.gov/23825729/)]. [PubMed Central: [PMC3696847](https://pubmed.ncbi.nlm.nih.gov/PMC3696847/)].
- Fawley WN, Knettsch CW, MacCannell DR, Harmanus C, Du T, Mulvey MR, et al. Development and validation of an internationally standardized, high-resolution capillary gel-based electrophoresis PCR-ribotyping protocol for Clostridium difficile. *PLoS One*. 2015;**10**(2). e0118150. doi: [10.1371/journal.pone.0118150](https://doi.org/10.1371/journal.pone.0118150). [PubMed: [25679978](https://pubmed.ncbi.nlm.nih.gov/25679978/)]. [PubMed Central: [PMC4332677](https://pubmed.ncbi.nlm.nih.gov/PMC4332677/)].
- Azimirad M, Krutova M, Nyc O, Hasani Z, Afrisham L, Alebouyeh M, et al. Molecular typing of Clostridium difficile isolates cultured from patient stool samples and gastroenterological medical devices in a single Iranian hospital. *Anaerobe*. 2017;**47**:125-8. doi: [10.1016/j.anaerobe.2017.05.004](https://doi.org/10.1016/j.anaerobe.2017.05.004). [PubMed: [28501554](https://pubmed.ncbi.nlm.nih.gov/28501554/)].
- Spigaglia P, Mastrantonio P. Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. *J Clin Microbiol*. 2002;**40**(9):3470-5. [PubMed: [12202595](https://pubmed.ncbi.nlm.nih.gov/12202595/)]. [PubMed Central: [PMC130716](https://pubmed.ncbi.nlm.nih.gov/PMC130716/)].
- Goudarzi M, Goudarzi H, Albouyeh M, Azimi Rad M, Zali MR, Aslan MM. [Molecular typing of Clostridium difficile isolated from hospitalized patients by PCR ribotyping]. *Res Med*. 2012;**36**(2):68-75. Persian.
- Indra A, Huhulescu S, Schneeweis M, Hasenberger P, Kernbichler S, Fiedler A, et al. Characterization of Clostridium difficile isolates using capillary gel electrophoresis-based PCR ribotyping. *J Med Microbiol*. 2008;**57**(Pt 11):1377-82. doi: [10.1099/jmm.0.47714-0](https://doi.org/10.1099/jmm.0.47714-0). [PubMed: [18927415](https://pubmed.ncbi.nlm.nih.gov/18927415/)]. [PubMed Central: [PMC2884938](https://pubmed.ncbi.nlm.nih.gov/PMC2884938/)].
- Versalovic J, Koeuth T, Lupski JR. Distribution of repetitive DNA sequences in eubacteria and application to fingerprinting of bacterial genomes. *Nucleic Acids Res*. 1991;**19**(24):6823-31. [PubMed: [1762913](https://pubmed.ncbi.nlm.nih.gov/1762913/)]. [PubMed Central: [PMC329316](https://pubmed.ncbi.nlm.nih.gov/PMC329316/)].
- Hunter PR, Gaston MA. Numerical index of the discriminatory ability of typing systems: An application of Simpson's index of diversity. *J Clin Microbiol*. 1988;**26**(11):2465-6. [PubMed: [3069867](https://pubmed.ncbi.nlm.nih.gov/3069867/)]. [PubMed Central: [PMC266921](https://pubmed.ncbi.nlm.nih.gov/PMC266921/)].
- Barbut F, Petit JC. Epidemiology of Clostridium difficile-associated infections. *Clin Microbiol Infect*. 2001;**7**(8):405-10. [PubMed: [11591202](https://pubmed.ncbi.nlm.nih.gov/11591202/)].
- Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: Is there a relationship with inflammatory bowel disease? *Therap Adv Gastroenterol*. 2013;**6**(1):53-68. doi: [10.1177/1756283X12454590](https://doi.org/10.1177/1756283X12454590). [PubMed: [23320050](https://pubmed.ncbi.nlm.nih.gov/23320050/)]. [PubMed Central: [PMC3539291](https://pubmed.ncbi.nlm.nih.gov/PMC3539291/)].
- Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: A review. *Altern Med Rev*. 2004;**9**(2):180-97. [PubMed: [15253677](https://pubmed.ncbi.nlm.nih.gov/15253677/)].
- Rutala WA, Gergen MF, Weber DJ. Inactivation of Clostridium difficile spores by disinfectants. *Infect Contr Hosp Epidemiol*. 1993;**14**(1):36-9. doi: [10.2307/30146511](https://doi.org/10.2307/30146511).
- Patterson DJ, Johnson EH, Schmulen AC. Fulminant pseudomembranous colitis occurring after colonoscopy. *Gastrointest Endosc*. 1984;**30**(4):249-53. [PubMed: [6479547](https://pubmed.ncbi.nlm.nih.gov/6479547/)].
- Dumford DM 3rd, Nerandzic MM, Eckstein BC, Donskey CJ. What is on that keyboard? Detecting hidden environmental reservoirs of Clostridium difficile during an outbreak associated with North American pulsed-field gel electrophoresis type 1 strains. *Am J Infect Control*. 2009;**37**(1):15-9. doi: [10.1016/j.ajic.2008.07.009](https://doi.org/10.1016/j.ajic.2008.07.009). [PubMed: [1917247](https://pubmed.ncbi.nlm.nih.gov/1917247/)].
- Warrack S, Duster M, Van Hoof S, Schmitz M, Safdar N. Clostridium difficile in a children's hospital: Assessment of environmental contamination. *Am J Infect Control*. 2014;**42**(7):802-4. doi: [10.1016/j.ajic.2014.03.008](https://doi.org/10.1016/j.ajic.2014.03.008). [PubMed: [24751141](https://pubmed.ncbi.nlm.nih.gov/24751141/)].
- Cartman ST, Heap JT, Kuehne SA, Cockayne A, Minton NP. The emergence of 'hypervirulence' in Clostridium difficile. *Int J Med Microbiol*. 2010;**300**(6):387-95. doi: [10.1016/j.ijmm.2010.04.008](https://doi.org/10.1016/j.ijmm.2010.04.008). [PubMed: [20547099](https://pubmed.ncbi.nlm.nih.gov/20547099/)].
- Lessa FC, Gould CV, McDonald LC. Current status of Clostridium difficile infection epidemiology. *Clin Infect Dis*. 2012;**55** Suppl 2:S65-70. doi: [10.1093/cid/cis319](https://doi.org/10.1093/cid/cis319). [PubMed: [22752867](https://pubmed.ncbi.nlm.nih.gov/22752867/)]. [PubMed Central: [PMC3388017](https://pubmed.ncbi.nlm.nih.gov/PMC3388017/)].
- Killgore G, Thompson A, Johnson S, Brazier J, Kuijper E, Pepin J, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile: Restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable-number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. *J Clin Microbiol*. 2008;**46**(2):431-7.

- doi: [10.1128/JCM.01484-07](https://doi.org/10.1128/JCM.01484-07). [PubMed: [18039796](https://pubmed.ncbi.nlm.nih.gov/18039796/)]. [PubMed Central: [PMC2238077](https://pubmed.ncbi.nlm.nih.gov/PMC2238077/)].
29. Brazier JS. Typing of *Clostridium difficile*. *Clin Microbiol Infect*. 2001;**7**(8):428-31. [PubMed: [11591206](https://pubmed.ncbi.nlm.nih.gov/11591206/)].
 30. Tenover FC, Akerlund T, Gerding DN, Goering RV, Bostrom T, Jons-son AM, et al. Comparison of strain typing results for *Clostridium difficile* isolates from North America. *J Clin Microbiol*. 2011;**49**(5):1831-7. doi: [10.1128/JCM.02446-10](https://doi.org/10.1128/JCM.02446-10). [PubMed: [21389155](https://pubmed.ncbi.nlm.nih.gov/21389155/)]. [PubMed Central: [PMC3122689](https://pubmed.ncbi.nlm.nih.gov/PMC3122689/)].
 31. Chia JH, Lai HC, Su LH, Kuo AJ, Wu TL. Molecular epidemiology of *Clostridium difficile* at a medical center in Taiwan: Persistence of genetically clustering of A(-)B(+) isolates and increase of A(+)B(+) isolates. *PLoS One*. 2013;**8**(10). e75471. doi: [10.1371/journal.pone.0075471](https://doi.org/10.1371/journal.pone.0075471). [PubMed: [24116048](https://pubmed.ncbi.nlm.nih.gov/24116048/)]. [PubMed Central: [PMC3792110](https://pubmed.ncbi.nlm.nih.gov/PMC3792110/)].
 32. Green LM, Worthington T, Hilton AC, Lambert PA. Genetic characterization of clinical isolates of *Clostridium difficile* using an optimized RAPD protocol and PCR ribotyping reveals strain diversity between two tertiary referral trusts in the West Midlands, UK. *J Med Microbiol*. 2011;**60**(Pt 9):1287-91. doi: [10.1099/jmm.0.030999-0](https://doi.org/10.1099/jmm.0.030999-0). [PubMed: [21511887](https://pubmed.ncbi.nlm.nih.gov/21511887/)].
 33. Janezic S, Ocepek M, Zidaric V, Rupnik M. *Clostridium difficile* genotypes other than ribotype 078 that are prevalent among human, animal and environmental isolates. *BMC Microbiol*. 2012;**12**:48. doi: [10.1186/1471-2180-12-48](https://doi.org/10.1186/1471-2180-12-48). [PubMed: [22452857](https://pubmed.ncbi.nlm.nih.gov/22452857/)]. [PubMed Central: [PMC3353227](https://pubmed.ncbi.nlm.nih.gov/PMC3353227/)].
 34. Bidet P, Lalande V, Salauze B, Burghoffer B, Avesani V, Delmee M, et al. Comparison of PCR-ribotyping, arbitrarily primed PCR, and pulsed-field gel electrophoresis for typing *Clostridium difficile*. *J Clin Microbiol*. 2000;**38**(7):2484-7. [PubMed: [10878030](https://pubmed.ncbi.nlm.nih.gov/10878030/)]. [PubMed Central: [PMC86949](https://pubmed.ncbi.nlm.nih.gov/PMC86949/)].
 35. van Dijk P, Avesani V, Delmee M. Genotyping of outbreak-related and sporadic isolates of *Clostridium difficile* belonging to serogroup C. *J Clin Microbiol*. 1996;**34**(12):3049-55. [PubMed: [8940447](https://pubmed.ncbi.nlm.nih.gov/8940447/)]. [PubMed Central: [PMC229458](https://pubmed.ncbi.nlm.nih.gov/PMC229458/)].
 36. Barbut F, Mario N, Delmee M, Gozian J, Petit JC. Genomic fingerprinting of *Clostridium difficile* isolates by using a random amplified polymorphic DNA (RAPD) assay. *FEMS Microbiol Lett*. 1993;**114**(2):161-6. [PubMed: [8282184](https://pubmed.ncbi.nlm.nih.gov/8282184/)].
 37. Rahmati A, Gal M, Northey G, Brazier JS. Subtyping of *Clostridium difficile* polymerase chain reaction (PCR) ribotype 001 by repetitive extragenic palindromic PCR genomic fingerprinting. *J Hosp Infect*. 2005;**60**(1):56-60. doi: [10.1016/j.jhin.2004.09.034](https://doi.org/10.1016/j.jhin.2004.09.034). [PubMed: [15823658](https://pubmed.ncbi.nlm.nih.gov/15823658/)].
 38. Fawley WN, Wilcox MH. Molecular epidemiology of endemic *Clostridium difficile* infection. *Epidemiol Infect*. 2001;**126**(3):343-50. [PubMed: [11467790](https://pubmed.ncbi.nlm.nih.gov/11467790/)]. [PubMed Central: [PMC2869701](https://pubmed.ncbi.nlm.nih.gov/PMC2869701/)].
 39. Stubbs SL, Brazier JS, O'Neill GL, Duerden BI. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of *Clostridium difficile* and construction of a library consisting of 116 different PCR ribotypes. *J Clin Microbiol*. 1999;**37**(2):461-3. [PubMed: [9889244](https://pubmed.ncbi.nlm.nih.gov/9889244/)]. [PubMed Central: [PMC84342](https://pubmed.ncbi.nlm.nih.gov/PMC84342/)].
 40. Terhes G, Brazier JS, Urban E, Soki J, Nagy E. Distribution of *Clostridium difficile* PCR ribotypes in regions of Hungary. *J Med Microbiol*. 2006;**55**(Pt 3):279-82. doi: [10.1099/jmm.0.46141-0](https://doi.org/10.1099/jmm.0.46141-0). [PubMed: [16476791](https://pubmed.ncbi.nlm.nih.gov/16476791/)].
 41. Martirosian G, Kuipers S, Verbrugh H, van Belkum A, Meisel-Mikolajczyk F. PCR ribotyping and arbitrarily primed PCR for typing strains of *Clostridium difficile* from a Polish maternity hospital. *J Clin Microbiol*. 1995;**33**(8):2016-21. [PubMed: [7559940](https://pubmed.ncbi.nlm.nih.gov/7559940/)]. [PubMed Central: [PMC228327](https://pubmed.ncbi.nlm.nih.gov/PMC228327/)].
 42. Rotimi VO, Jamal WY, Mokaddas EM, Brazier JS, Johnny M, Duerden BI. Prevalent PCR ribotypes of clinical and environmental strains of *Clostridium difficile* isolated from intensive-therapy unit patients in Kuwait. *J Med Microbiol*. 2003;**52**(Pt 8):705-9. doi: [10.1099/jmm.0.05207-0](https://doi.org/10.1099/jmm.0.05207-0). [PubMed: [12867566](https://pubmed.ncbi.nlm.nih.gov/12867566/)].
 43. Barbut F, Mastrantonio P, Delmee M, Brazier J, Kuijper E, Poxton I, et al. Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clin Microbiol Infect*. 2007;**13**(11):1048-57. doi: [10.1111/j.1469-0691.2007.01824.x](https://doi.org/10.1111/j.1469-0691.2007.01824.x). [PubMed: [17850341](https://pubmed.ncbi.nlm.nih.gov/17850341/)].
 44. Brazier JS, Patel B, Pearson A. Distribution of *Clostridium difficile* PCR ribotype 027 in British hospitals. *Euro Surveill*. 2007;**12**(4). E070426 2. [PubMed: [17868609](https://pubmed.ncbi.nlm.nih.gov/17868609/)].